Hyperuricemia and risk of incident hypertension: A systematic review and meta-analysis of observational studies

PLoS ONE

Volumn 9, Issue 12, 2014, Pages

  Wang, Ji ^a   Qin, Tianqiang ^a   Chen, Jianrong ^a   Li, Yulin ^b   Wang, Ling ^c   Huang, He ^a   Li, Jing ^a  

^a SICHUAN UNIVERSITY   (China)

^b CHENGDU UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c Department of Internal Medicine   (China)

Author keywords

[No Author keywords available]

Indexed keywords

URIC ACID;

ARTICLE; CASE CONTROL STUDY; COHORT ANALYSIS; DISEASE ASSOCIATION; EFFECT SIZE; HUMAN; HYPERTENSION; HYPERURICEMIA; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; RISK FACTOR; SYSTEMATIC REVIEW; BLOOD; COMPLICATION; INCIDENCE; META ANALYSIS; RISK;

HUMANS; HYPERTENSION; HYPERURICEMIA; INCIDENCE; RISK; URIC ACID;

EID: 84914695409     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0114259     Document Type: Article

References (46)

1. Mahomed FA (1879) On chronic Bright's disease, and its essential symptoms. Lancet 1: 399-401.
2. Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, et al. (2008) Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin-angiotensin system. J Hypertens 26: 269-275.
3. Kang DH, Park SK, Lee IK, Johnson RJ (2005) Uric acid-induced C-reactive protein expression: implication on cell proliferation and nitric oxide production of human vascular cells. J Am Soc Nephrol 16: 3553-3562.
4. Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, et al. (2005) Hyperuricemia induces endothelial dysfunction. Kidney Int 67: 1739-1742.
5. Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, et al. (2001) Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38: 1101-1106.
6. Rao GN, Corson MA, Berk BC (1991) Uric acid stimulates vascular smooth muscle cell proliferation by increasing platelet-derived growth factor A-chain expression. J Biol Chem 266: 8604-8608.
7. Sanchez-Lozada LG, Tapia E, Santamaria J, Avila-Casado C, Soto V, et al. (2005) Mild hyperuricemia induces vasoconstriction and maintains glomerular hypertension in normal and remnant kidney rats. Kidney Int 67: 237-247.
8. Feig DI, Kang DH, Johnson RJ (2008) Uric acid and cardiovascular risk. N Engl J Med 359: 1811-1821.
9. Forman JP, Choi H, Curhan GC (2007) Plasma uric acid level and risk for incident hypertension among men. J Am Soc Nephrol 18: 287-292.
10. Johnson RJ, Feig DI, Herrera-Acosta J, Kang DH (2005) Resurrection of uric acid as a causal risk factor in essential hypertension. Hypertension 45: 18-20.
11. Grayson PC, Kim SY, LaValley M, Choi HK (2011) Hyperuricemia and incident hypertension: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 63: 102-110.
12. Wu YT, Wu SL, Li Y, Jin C, Zhang YM, et al. (2010) The relationship between serum uric acid and the progression of blood pressure in patients with prehypertension. Chin J Hypertens 18: 545-549.
13. Chien KL, Hsu HC, Su TC, Chang WT, Sung FC, et al. (2011) Prediction models for the risk of new-onset hypertension in ethnic Chinese in Taiwan. J Hum Hypertens 25: 294-303.
14. Yang T, Chu CH, Bai CH, You SL, Chou YC, et al. (2012) Uric acid concentration as a risk marker for blood pressure progression and incident hypertension: a Chinese cohort study. Metabolism 61: 1747-1755.
15. Gaffo AL, Jacobs DR, Sijtsma F, Lewis CE, Mikuls TR, et al. (2013) Serum urate association with hypertension in young adults: analysis from the Coronary Artery Risk Development in Young Adults cohort. Ann Rheum Dis 72: 1321-1327.
16. Stroup DF, Berlin JA, Morton SC, Olkin I, Williamson GD, et al. (2000) Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 283: 2008-2012.
17. Moher D, Liberati A, Tetzlaff J, Altman DG (2010) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 8: 336-341.
18. Wells GA., Shea B, O'Connell D, Peterson J, Welch V, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available: http://www.ohri.ca/programs/clinical-epidemiology/oxford.asp. Accessed 10 November 2014.
19. Greenland S (1987) Quantitative methods in the review of epidemiologic literature. Epidemiol Rev 9: 1-30.
20. DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177-188.
21. Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629-634.
22. Duval S, Tweedie R (2000) A nonparametric "trim and fill" method of accounting for publication bias in meta-analysis. J Am Stat Assoc 95: 89-98.
23. Kahn HA, Medalie JH, Neufeld HN, Riss E, Goldbourt U (1972) The incidence of hypertension and associated factors: the Israel ischemic heart disease study. Am Heart J 84: 171-182.
24. Fessel WJ (1980) High uric acid as an indicator of cardiovascular disease. Independence from obesity. Am J Med 68: 401-404.
25. Selby JV, Friedman GD, Quesenberry CP (1990) Precursors of essential hypertension: pulmonary function, heart rate, uric acid, serum cholesterol, and other serum chemistries. Am J Epidemiol 131: 1017-1027.
26. Hunt SC, Stephenson SH, Hopkins PN, Williams RR (1991) Predictors of an increased risk of future hypertension in Utah. A screening analysis. Hypertension 17: 969-976.
27. Jossa F, Farinaro E, Panico S, Krogh V, Celentano E, et al. (1994) Serum uric acid and hypertension: the Olivetti heart study. J Hum Hypertens 8: 677-681.
28. Nakanishi N, Nakamura K, Ichikawa S, Suzuki K, Kawashimo H, et al. (1998) Risk factors for the development of hypertension: a 6-year longitudinal study of middle-aged Japanese men. J Hypertens 16: 753-759.
29. Dyer AR, Liu K, Walsh M, Kiefe C, Jacobs DR, et al. (1999) Ten-year incidence of elevated blood pressure and its predictors: the CARDIA study. Coronary Artery Risk Development in (Young) Adults. J Hum Hypertens 13: 13-21.
30. Imazu M, Yamamoto H, Toyofuku M, Sumii K, Okubo M, et al. (2001) Hyperinsulinemia for the development of hypertension: data from the Hawaii-Los Angeles-Hiroshima Study. Hypertens Res 24: 531-536.
31. Taniguchi Y, Hayashi T, Tsumura K, Endo G, Fujii S, et al. (2001) Serum uric acid and the risk for hypertension and Type 2 diabetes in Japanese men: The Osaka Health Survey. J Hypertens 19: 1209-1215.
32. Yeh CJ, Pan WH, Jong YS, Kuo YY, Lo CH (2001) Incidence and predictors of isolated systolic hypertension and isolated diastolic hypertension in Taiwan. J Formos Med Assoc 100: 668-675.
33. Zhang H, Li Y, Tao S, Zhou B, Folsom AR, et al. (2001) Relationship of serum uric acid to 4-year incidence of hypertension and blood pressure change in a Chinese population. Chin J Hypertens 9: 160-163.
34. Nakanishi N, Okamoto M, Yoshida H, Matsuo Y, Suzuki K, et al. (2003) Serum uric acid and risk for development of hypertension and impaired fasting glucose or Type II diabetes in Japanese male office workers. Eur J Epidemiol 18: 523-530.
35. Nagahama K, Inoue T, Iseki K, Touma T, Kinjo K, et al. (2004) Hyperuricemia as a predictor of hypertension in a screened cohort in Okinawa, Japan. Hypertens Res 27: 835-841.
36. Sundstrom J, Sullivan L, D'Agostino RB, Levy D, Kannel WB, et al. (2005) Relations of serum uric acid to longitudinal blood pressure tracking and hypertension incidence. Hypertension 45: 28-33.
37. Mellen PB, Bleyer AJ, Erlinger TP, Evans GW, Nieto FJ, et al. (2006) Serum uric acid predicts incident hypertension in a biethnic cohort: the atherosclerosis risk in communities study. Hypertension 48: 1037-1042.
38. Perlstein TS, Gumieniak O, Williams GH, Sparrow D, Vokonas PS, et al. (2006) Uric acid and the development of hypertension: the normative aging study. Hypertension 48: 1031-1036.
39. Shankar A, Klein R, Klein BEK, Nieto FJ (2006) The association between serum uric acid level and long-term incidence of hypertension: Population-based cohort study. J Hum Hypertens 20: 937-945.
40. Krishnan E, Kwoh CK, Schumacher HR, Kuller L (2007) Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 49: 298-303.
41. Forman JP, Choi H, Curhan GC (2009) Uric acid and insulin sensitivity and risk of incident hypertension. Arch Intern Med 169: 155-162.
42. Zhang W, Sun K, Yang Y, Zhang H, Hu FB, et al. (2009) Plasma uric acid and hypertension in a Chinese community: prospective study and metaanalysis. Clin Chem 55: 2026-2034.
43. Johnson RJ, Rodriguez-Iturbe B, Kang DH, Feig DI, Herrera-Acosta J (2005) A unifying pathway for essential hypertension. Am J Hypertens 18: 431-440.
44. Watanabe S, Kang DH, Feng L, Nakagawa T, Kanellis J, et al. (2002) Uric acid, hominoid evolution, and the pathogenesis of salt-sensitivity. Hypertension 40: 355-360.
45. Feig DI, Nakagawa T, Karumanchi SA, Oliver WJ, Kang DH, et al. (2004) Hypothesis: Uric acid, nephron number, and the pathogenesis of essential hypertension. Kidney Int 66: 281-287.
46. Feig DI, Soletsky B, Johnson RJ (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300: 924-932.